Immune response in ADEPT
- 1 December 1996
- journal article
- review article
- Published by Elsevier in Advanced Drug Delivery Reviews
- Vol. 22 (3), 369-376
- https://doi.org/10.1016/s0169-409x(96)00440-1
Abstract
No abstract availableThis publication has 31 references indexed in Scilit:
- In vivo immunosuppression by targeting a novel protease receptorNature, 1996
- Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: A note of cautionLife Sciences, 1994
- Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal AntibodiesCancer Biotherapy, 1994
- Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non-small-cell lung, colon, and breast cancerCancer Immunology, Immunotherapy, 1993
- The use of monoclonal antibodies to achieve immunological toleranceImmunology Today, 1993
- Experience with Mycophenolate Mofetil (RS61443) in Renal Transplantation at a Single CenterAnnals of Surgery, 1993
- Human IgM Monoclonal Antibody 16.88: Pharmacokinetics and Immunogenicity in Colorectal Cancer PatientsJNCI Journal of the National Cancer Institute, 1991
- PRECLINICAL EVALUATION OF A NEW POTENT IMMUNOSUPPRESSIVE AGENT, RAPAMYCINTransplantation, 1991
- A phase‐i study of repeated therapy with radiolabelled antibody to carcinoembryonic antigen using intermittent or continuous administration of cyclosporin a to suppress the immune responseInternational Journal of Cancer, 1991
- Tolerogenic conjugates of xenogeneic monoclonal antibodies with monomethoxypolyethylene glycol. I. Induction of long-lasting tolerance to xenogeneic monoclonal antibodiesInternational Journal of Cancer, 1988